louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03331653: Effectiveness of Dry Needling and Ischemic Compression in Sternocleidomastoid, on Cervical Motor Control in Patients With Cervical Pain.
Official title: Effectiveness of Dry Needling and Ischemic Compression in the Sternocleidomastoid, on Cervical Motor Control in Patients With Cervical Pain, Versus Placebo Technique and Ischemic Compression, Randomized Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Pain
Keywords: Cervical Pain
Motor Control
Sternocleidomastoid
Dry Needling
Lead sponsor: University of Alcala
Sponsor class: OTHER
First posted: 2017-11-06
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized Clinical Trial (RCT) with two groups.
Primary purpose: TREATMENT

Brief summary: This study will compare the effect of dry needling on the active trigger point on sternocleidomastoid versus the effect of dry needling at 1.5 centimeters of active trigger point on sternocleidomastoid, both combined with ischemic compression, on cervical pain and cervical motor control short and medium term.


Eligibility criteria: Inclusion Criteria:

* Be between 18 and 65 years old
* Have pain in the cervical region, which extends from the occipital to the 7th cervical vertebra.
* Have an active trigger point on the sternocleidomastoid.

Exclusion Criteria:

* Present history of trauma in the neck.
* Present cervical radiculopathy
* Present a vestibular pathology
* Previous surgery on the neck or shoulder area
* Having a primary headache diagnosis
* Have received dry needling in the neck in the previous 6 months
* Present cognitive deficit.
* Be pregnant
* Taking anticoagulants.
* Have phobia to the needles (belonephobia).

Primary outcomes:
measure: Cervical Pain
timeFrame: Pre-intervention, immediately post-intervention, 1 day, 1 week, 1 month
measure: Cervical Motor Control
timeFrame: Pre-intervention, immediately post-intervention, 1 day, 1 week, 1 month
Secondary outcomes:
measure: Cervical Range of Movement
timeFrame: Pre-intervention, immediately post-intervention, 1 day, 1 week, 1 month
measure: Coordination of superficial and deep cervical flexor muscles
timeFrame: Pre-intervention, immediately post-intervention, 1 day, 1 week, 1 month
measure: Cervical Disability
timeFrame: Pre-intervention,1 month
Other outcomes:
Locations:
city: Alcalá de Henares
country: Spain
facility: University of Alcalá
state: Madrid
Study officials:
affiliation: Investigator
name: Aida M. Rodríguez, Physiotherapy
role: PRINCIPAL_INVESTIGATOR
affiliation: Investigator
name: Esther S. Olmo, Physiotherapy
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00211653: Acetylcysteine in the Prevention of Renal Failure After Bypass Surgery
Official title: Single Center Randomized Clinical Trial of the Effects of Acetylcysteine in the Prevention of Postoperative Renal Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Kidney Failure
Keywords: Kidney failure
Thoracic surgery
Acetylcysteine
Lead sponsor: Minneapolis Veterans Affairs Medical Center
Sponsor class: FED
First posted: 2005-09-21
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if Acetylcysteine is effective in preventing renal failure associated with cardiac surgery

Detailed description: Postoperative renal dysfunction is a predictor of significant morbidity and mortality among patients undergoing cardiac surgery. The mortality associated with coronary artery by-pass surgery increases from 2% to almost 19% in patients with renal failure and approaches 60% in patients who require hemodialysis. Patients with preoperative renal dysfunction referred for coronary artery by pass surgery have an extraordinarily high risk of requiring postoperative dialysis. For example, among those patients with preoperative creatinine \>2.5 mg/dL, almost 50% require hemodialysis.

Comparison: N-Acetylcysteine is superior to placebo in preventing renal failure after cardiac surgery

Eligibility criteria: Inclusion Criteria:

* Pts with baseline chronic kidney disease (eGFR\<60 ml/min/1.73m2)undergoing cardiac surgery

Exclusion Criteria:

* Patients on hemodialysis preoperatively
* IV contrast within 4 days prior to surgery
* Urgent/emergent surgery
* History of renal transplantation

Primary outcomes:
measure: Rise in creatinine above baseline
timeFrame: 7 days postoperatively
Secondary outcomes:
measure: Creatinine increase >25% or =/> 0.5 mg/dl above baseline
timeFrame: Postoperative days 5, 7 and 30
measure: Length of stay in the ICU and the hospital
measure: Operative mortality
timeFrame: 30-day
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Veterans Affairs Medical Center
state: Minnesota
Study officials:
affiliation: Minneapolis Veterans Affairs Medical Center
name: Selcuk Adabag, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Adabag AS, Ishani A, Koneswaran S, Johnson DJ, Kelly RF, Ward HB, McFalls EO, Bloomfield HE, Chandrashekhar Y. Utility of N-acetylcysteine to prevent acute kidney injury after cardiac surgery: a randomized controlled trial. Am Heart J. 2008 Jun;155(6):1143-9. doi: 10.1016/j.ahj.2008.01.013. Epub 2008 Mar 5.
Clinical trial NCT04357353: The Role of Platelet Rich Plasma for Erectile Dysfunction
Official title: The Role of Platelet Rich Plasma for Erectile Dysfunction
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Erectile Dysfunction
Lead sponsor: University of Nebraska
Sponsor class: OTHER
First posted: 2020-04-22
Enrollment: 13
Sex: MALE
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized Controlled Trial
Primary purpose: TREATMENT

Brief summary: Purpose of Study: This randomized controlled trial investigates the role that platelet rich plasma injections into the penis may play to improve erectile function in men with erectile dysfunction.

Detailed description: Eligibility: Men with erectile dysfunction. Ages 50-80. International Index of Erectile Function score of mild (17-21/25) or moderate (8-16/25).

Intervention and Evaluation:Men who consent to join the trial will be randomized to receive either a single injection PRP or saline to the penis. All patients will have blood drawn in clinic the day of injection. Those randomized to PRP arm will have their own blood prepared and separated into the PRP. This solution of their own blood will be injected back into the penis.

Follow Up: Men will be evaluated at 1 , 3, and 6 months after the injections and then asked to complete the IIEF by phone or by electronic means

Eligibility criteria: Inclusion Criteria:

* history of mild to moderate erectile dysfunction measured by IIEF

Exclusion Criteria:

* history or prostate cancer treatment (prostatectomy, radiation, brachytherapy)

Primary outcomes:
measure: Erectile Function Change
timeFrame: at 1, 3 and 6 months
Secondary outcomes:
Other outcomes:
measure: Side Effects
timeFrame: at 1, 3 and 6 months
Locations:
city: Omaha
country: United States
facility: Unversity of Nebraska Medical Center
state: Nebraska
Study officials:
affiliation: University of Nebraska
name: Chris Deibert, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05150353: Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP)
Official title: Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Amyloid
Systemic Amyloidosis
Lead sponsor: Ramsay Générale de Santé
Sponsor class: OTHER
Collaborators: name: European Clinical Trial Experts Network
First posted: 2021-12-09
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: This study is based on the hypothesis that MRI could make it possible to non-invasively detect these amyloid deposits at the level of the wrist using parametric sequences known as T1 mapping, in the form of an extension of T1 in the wrists. areas where amyloid deposits are found in the wrist.


Eligibility criteria: Inclusion Criteria:

Patient group:

* Woman or man over 18 years old
* With ATTR or AL cardiac amyloidosis with or without carpal tunnel. The diagnosis of amyloidosis must be proven by a positive myocardial biopsy or diphosphonate scintigraphy.
* Affiliate or beneficiarie of a social security scheme.
* Having signed the free and informed consent.

Healthy volunteers:

* Woman or man over 18 years old
* Affiliate or beneficiarie of a social security scheme.
* Having signed the free and informed consent.

Exclusion Criteria:

Patient group:

* Patients participating in another clinical study.
* Patients suffering from rheumatoid arthritis or other autoimmune disease (vasculitis, lupus, scleroderma, etc.)
* Patients with a medical history of wrist surgery (exclude the operated side).
* Patients with a contraindication to performing an MRI (pacemaker, etc.)
* Pregnant or breastfeeding women.
* Protected patients: Adults under guardianship, curatorship or other legal protection, deprived of their liberty by judicial or administrative decision.

Healthy volunteer:

* Volunteers participating in another clinical study.
* Volunteers suffering from rheumatoid arthritis or other autoimmune disease (vasculitis, lupus, scleroderma, etc.)
* Pregnant or breastfeeding women.
* Volunteer with a contraindication to performing an MRI (pacemaker, etc.)
* Protected volunteers: Adults under guardianship, guardianship or other legal protection, deprived of their liberty by judicial or administrative decision.

Primary outcomes:
measure: T1 measurement (ms) associated with each of the 5 regions of interest at the wrist
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Champigny-sur-Marne
country: France
facility: Hôpital Privé Paul d'Egine
Study officials:
References:
Clinical trial NCT02781753: Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers
Official title: A Phase 1 Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Safety, and Tolerability of Escalating Single Dose Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Healthy Chinese Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Tianjin SinoBiotech Ltd.
Sponsor class: INDUSTRY
First posted: 2016-05-24
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the dosages of recombinant human serum albumin/interferon alpha2b fusion protein injection in healthy subjects.

Detailed description: This is an open-label study that will be conducted at a single site in China to characterize the PK/PD profile, safety and tolerability of Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein in healthy subjects. Subjects will receive a single dose of Recombinant Human Serum Albumin/interferon alpha2b Fusion Protein or active comparator Pegasys at Day 0. The total duration of study participation is up to 6 weeks for each subject. Subjects will complete a follow-up visit at Day 28 after the dosing.

Eligibility criteria: Inclusion Criteria:

* Must be healthy males or females between 18 to 45 years old, inclusive
* Must have a body mass index (BMI) of 19 to 25 kg/m2, inclusive, and a minimum body weight of 50.0 kg

Exclusion Criteria:

* History of any clinically significant laboratory abnormalities, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major diseases
* Female subjects who are pregnant or breastfeeding
* Any previous treatment with Human Albumin Interferon fusion protein

Primary outcomes:
measure: Number of participants with adverse events after single dose
timeFrame: 4 weeks
Secondary outcomes:
measure: Pharmacokinetics of interferon after single dose
timeFrame: 4 weeks
measure: Pharmacokinetics of interferon after single dose
timeFrame: 4 weeks
measure: Plasma concentration of Neopterin after single dose
timeFrame: 4 weeks
measure: Pharmacokinetics of interferon after single dose
timeFrame: 4 weeks
measure: Pharmacokinetics of interferon after single dose
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing YouAn Hospital, Capital Medical University
state: Beijing
Study officials:
affiliation: Beijing YouAn Hospital
name: Meixia Wang, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01130753: Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer
Official title: A Phase II Trial of Neoadjuvant Erlotinib (Tarceva®) Followed by Surgery for Selected Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Lung Neoplasms
Erlotinib
Neoadjuvant Therapy
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2010-05-26
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study propose neoadjuvant chemotherapeutic role by erlotinib.

Detailed description: It is widely accepted that patients with locally advanced non-small cell lung cancer would have better outcome with neoadjuvant therapy followed by surgery than surgery alone. However what should be the standard treatment option is still unclear.

Erlotinib (Tarceva®)is an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase and its anti-neoplastic effect is approved especially women, patients with adenocarcinoma, non-smoker and Asian population. Moreover if the malignant tissue has EGFR mutation, its efficacy is known to be enhanced.

So we expect that in those population, patients with locally advanced, N2 positive, erlotinib would be more beneficial than conventional cytotoxic chemotherapy in safety and convenience as neoadjuvant therapy.

Eligibility criteria: Inclusion Criteria:

* Pathologically confirmed N2 positive and stage IIIA non-small cell lung cancer
* Has more than 2 conditions out of following 3 conditions ; adenocarcinoma, non-smoker, women
* Age ≥ 18 years and ECOG performance 0\~1
* Has measurable lesion by RECIST 1.1
* No previous chemotherapy or radiation therapy
* Adequate organ function by following; ANC ≥1,500/uL, hemoglobin ≥9.0g/dL, platelet ≥100,000/uL, PaO2 ≥ 60 mmHg, Serum Cr \< 1 x UNL or creatinine clearance \> 60 ml/min, Serum bilirubin \< 1 x UNL, AST (SGOT) and ALT (SGPT) \< 2.5 x UNL, alkaline phosphatase \< 5 x UNL
* Written informed consent form

Exclusion Criteria:

* Pulmonary carcinoid tumor
* Previous chemotherapy or radiation therapy
* Previous history of malignancy within 5 years from study entry except treated non-melanomatous skin cancer or uterine cervical cancer in situ
* Known allergic history of erlotinib
* Interstitial lung disease or fibrosis on chest radiogram
* Active infection, uncontrolled systemic disease (cardiopulmonary insufficiency, fatal arrhythmias, hepatitis)
* Pregnant or nursing women

Primary outcomes:
measure: Pathologic down-staging
timeFrame: 36 months
Secondary outcomes:
measure: Response rate
timeFrame: 36 months
measure: Toxicity
timeFrame: 36 months
measure: Progression free survival
timeFrame: 36 months
measure: Overall survival
timeFrame: 36 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
References:
Clinical trial NCT03160053: Improving Keloids Using Targeted Ultraviolet-B Irradiation
Official title: Improving Keloids Using Targeted Ultraviolet-B Irradiation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Keloid
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2017-05-19
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Each participant served as his/hers own control.
Primary purpose: TREATMENT

Brief summary: Treatment of keloids with targeted Ultraviolet-Beta (UVB) radiation will improve the clinical appearance and induration of lesions.


Eligibility criteria: Inclusion Criteria:

* Participants must be 18 years old or over
* Participants must have a diagnosis of keloid
* No treatment with topical or intralesional steroids for 1 month prior to study

Exclusion Criteria:

* Patients who are unable to provide informed consent
* A history of photosensitivity, lupus erythematosus, porphyria or current use of a known photosensitizing drug
* Unwillingness to stop with topical or intralesional steroids for 1 month prior to study
* A history of malignant melanoma
* A history of radiation therapy to area of interest
* Subjects who self-report that they are pregnant or nursing

Primary outcomes:
measure: Clinical Appearance As Assessed by the Patient and Observer Scar Assessment (POSAS) Scale
timeFrame: 16 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01206153: Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients
Official title: Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients: a Double Blind, Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Amenorrhea
Lead sponsor: Central South University
Sponsor class: OTHER
First posted: 2010-09-21
Enrollment: 84
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Antipsychotics such as risperidone could induce amenorrhea in schizophrenic patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of metformin for antipsychotic induced amenorrhea in schizophrenia patients.


Eligibility criteria: Inclusion Criteria:

* schizophrenia patient
* amenorrhea for more than three months after antipsychotic treatment

Exclusion Criteria:

* liver or renal diseases
* pregnant or lactating women
* cardiovascular diseases
* hypertension or diabetes mellitus

Primary outcomes:
measure: prolactin level
Secondary outcomes:
measure: fasting glucose
Other outcomes:
Locations:
city: Changsha
country: China
facility: Institute of Mental Health of The Second Xiangya Hospital, Central South University
state: Hunan
Study officials:
affiliation: Institute of Mental Health of The Second Xiangya Hospital, Central South University, 139# Renmin Middle Road，Changsha 410011, Hunan, P.R. China
name: Jingping Zhao, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04376177: Clinical Routine in Thoracic Outlet Syndrome
Official title: Evaluation Des Mesures Dopplers, Angiographiques, Radiographique Oximetriques, Plethysmographiques, Electromyographiques et Des Questionnaires Cliniques Des Patients adressés Pour Suspicion de Syndrome du défilé Thoraco-brachial
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Thoracic Outlet Syndrome
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2020-05-06
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adult subjects referred for the diagnosis or follow up of TOS

Brief summary: Transversal recording and analysis of investigations performed in patients referred for suspected thoracic outlet syndrome (TOS)

Detailed description: Patients will have recording on a database of all investigations that were eventually performed for the diagnosis or follow up of their disease, among which:

* Characteristics (Age, Gender height, weight, ongoing treatment ,
* professional activity, sports activity,
* Symptoms.
* Forearm and finger photoplethysmography (PPG) during provocative maneuvers of the upper limb
* Transcutaneous oxymetry (Tcpo2) recording
* Standard questionnaires (MASC, DASH, FS36)
* Doppler and ultrasound during provocative maneuvers of the upper limb
* Angiography during provocative maneuvers of the upper limb
* Electromyogram
* Standard X-ray

Eligibility criteria: Inclusion Criteria:

* Absence of deny for the use of medical filesfor research purposes

Exclusion Criteria:

* Inability to understand the purpose of the database.
* Patient protected by law.

Primary outcomes:
measure: ultrasound
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
measure: angiography encoding
timeFrame: 1 week
measure: Questionnaire scoring
timeFrame: 1 hour
measure: Transcutaneous oximetry
timeFrame: 1 hour
measure: Plethysmography interpretation
timeFrame: 1 hour
Locations:
city: Angers
country: France
facility: University Hospital
Study officials:
affiliation: University and univerity hospital in Angers, FRANCE
name: Pierre ABRAHAM, MD; PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hersant J, Ramondou P, Josse C, Lecoq S, Henni S, Abraham P. Quantitative analysis of venous outflow with photo-plethysmography in patients with suspected thoracic outlet syndrome. Front Cardiovasc Med. 2022 Oct 28;9:803919. doi: 10.3389/fcvm.2022.803919. eCollection 2022.